All

SumUp secures $100m credit facility to expand merchant cash advance product
9 August 2023

SumUp secures $100m credit facility to expand merchant cash advance product

The company says its latest offering, SumUp Cash Advance, will help merchants in the UK finance their operations by furnishing advances of up to £20,000 based on their payment...

Read more
IDnow receives ANSSI’s security approval for PVID certification for its identity proofing services IDCheck.io and VideoIdent
1 August 2023

IDnow receives ANSSI’s security approval for PVID certification for its identity proofing services IDCheck.io and VideoIdent

IDnow, a leading identity proofing platform provider in Europe, has obtained the remote identity verification certification known as PVID (prestataire de verification...

Read more
SumUp taps Form3 for access to UK Faster Payments, appoints CPO
7 July 2023

SumUp taps Form3 for access to UK Faster Payments, appoints CPO

UK-based SME paytech SumUp has partnered up with cloud-based payments platform Form3 to receive direct access to the UK Faster Payments Scheme (FPS) and Bacs Scheme.

Read more
Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer
30 June 2023

Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer

Enterome today announces that the first patient was dosed in the Phase 1/2 'AUDREY' trial evaluating EO4010, the Company's third OncoMimics™ candidate, for the treatment of...

Read the press release
Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
14 June 2023

Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry...

Read the press release
IDnow adds new features to its platform
7 June 2023

IDnow adds new features to its platform

Germany-based identity proofing platform provider IDnow has added new features to its platform to thwart sophisticated fraudulent attacks in the UK.

Read more
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis
23 May 2023

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

Galecto, Inc., a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today...

Read the press release
CyberKnight augments cyber risk quantification strategy with Citalid
10 May 2023

CyberKnight augments cyber risk quantification strategy with Citalid

To support Middle East organizations with predicting, understanding, and quantifying cyber risk

Read more
Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
9 May 2023

Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

Exploratory analyses from the VE303 Phase 2 CONSORTIUM study identify statistically significant relationships between VE303 bacterial species and multiple parameters that...

Read the press release